The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...
Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...
Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% ...
Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using ...
14h
Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy
Study supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in Stargardt disease ...
Sensorineural hearing loss (SNHL) is a highly prevalent sensory disorder globally, affecting over 1.5 billion people, with a ...
Sanofi (SAN:CA) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 12:45 PM ESTCompany ParticipantsPaul Hudson - CEO & ...
Verywell Health on MSN
Proteinuria in Complement 3 Glomerulopathy: Why It Matters and What to Do
Proteinuria (protein in urine) is common with complement 3 glomeropathy and is a strong predictor of disease progression and end-stage kidney failure.
Kanazawa University, have captured real-time images showing how a key brain enzyme organizes itself to help memory formation.
CBeyondTM Phase 2a 26-week extension data update and interim results expected Q1 2026. CBeyond Phase 2a Data Monitoring ...
6hon MSN
T cells gain superior memory through new reprogramming method, boosting cancer-fighting abilities
Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback